Cleared Traditional

K961393 - TRICYCLICS SERUM TOX ASSAY

K961393 is the FDA 510(k) clearance for TRICYCLICS SERUM TOX ASSAY by Diagnostic Reagents, Inc.. It is a Class 2 Toxicology device (product code LFH) cleared through the Traditional 510(k) pathway after a 62-day FDA review.

K961393 · Diagnostic Reagents, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1996
Decision
62d
Days
Class 2
Risk

K961393 is an FDA 510(k) clearance for the TRICYCLICS SERUM TOX ASSAY. Classified as U.v. Spectrometry, Tricyclic Antidepressant Drugs (product code LFH), Class II - Special Controls.

Submitted by Diagnostic Reagents, Inc. (Sunnyvale, US). The FDA issued a Cleared decision on June 12, 1996 after a review of 62 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3910 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Diagnostic Reagents, Inc. devices

Submission Details

510(k) Number K961393 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 11, 1996
Decision Date June 12, 1996
Days to Decision 62 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
25d faster than avg
Panel avg: 87d · This submission: 62d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LFH U.v. Spectrometry, Tricyclic Antidepressant Drugs
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3910
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - LFH U.v. Spectrometry, Tricyclic Antidepressant Drugs

Devices cleared under the same product code (LFH) and FDA review panel - the closest regulatory comparables to K961393.
DRI TM Tricyclics Serum Tox Assay
K213875 · Microgenics Corporation · Dec 2022
MODIFICATION OF TRICYCLIC SERUM TOX EIA ASSAY
K983268 · Diagnostic Reagents, Inc. · Nov 1998
ACCUSIGN TCA, BIOSIGN TCA, STAUS DS TCA
K981801 · Princeton BioMeditech Corp. · Aug 1998
AXSYM TRICYCLIC ANTIDEPRESSANTS
K953761 · Abbott Laboratories · Nov 1995